Horizon Domainex collaboration


Published on

Horizon and Domainex to collaborate on TBK1 IKKε oncology project

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Horizon Domainex collaboration

  1. 1. Horizon Discovery and Domainex Ltd Collaborate to Support Lead Optimization Oncology Program Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compoundsCambridge, UK, 06 August 2012: Horizon Discovery Ltd (Horizon), a leading provider ofresearch tools to support the development of personalized medicines, today announced it hassigned an agreement with Domainex to support Domainex’s TBK1/ IKKε oncology research anddevelopment program, which is conducted in collaboration with The Institute of Cancer Research,London. Under the terms of the agreement, Horizon will profile a number of lead compoundsagainst a panel of X-MAN™ isogenic disease model human cell lines, which accurately model themutations found in cancer cells.Profiling of Domainex’s lead TBK1/IKKε dual inhibitor molecules against the X-MAN cell lines willenable identification of the effect of individual mutations on drug activity and resistance andprediction of which patient sub-groups will respond. This will help guide the medicinal chemistryoptimization program and will provide important patient stratification data for future partnering.“Horizon’s oncology and genome editing expertise are a valuable complement to our in-housebiochemistry, medicinal chemistry and computer aided drug design capabilities,” commentedEddy Littler, CEO of Domainex. “We look forward to working together to efficiently and cost-effectively develop a drug molecule for this important target. We also look forward to futurecollaborations with Horizon on Domainex’s epigenetic pipeline in oncology and with the widenumber of projects that Domainex supports on behalf of its clients”Kam Dhaliwal, Director of Business Development, Horizon said: “We are delighted that Domainexhas chosen to collaborate with Horizon on their lead program, and look forward to leveraging ourDiscovery Toolbox and Oncology expertise to help guide the program.”Horizon’s Discovery Toolbox is based on its proprietary precision rAAV-mediated genome editingtechnology (GENESIS™), over 450 X-MAN human isogenic cell lines that more accurately modelpatient genetics (known as “patients in a test tube”), and 2D and 3D phenotypic assays. TheToolbox enables the recapitulation of the patient situation in vitro and allows screening of themost important activated cancer genes and pathways found in patients, under conditions thatmimic the micro environment of the disease.Financial terms of the agreement are not disclosed. ENDSNotes to EditorsContacts:At Horizon:Kam DhaliwalDirector of Business Development
  2. 2. Tel: +44 (0)1223 655 580Email: Kam.Dhaliwal@horizondiscovery.comMedia enquiries for Horizon:Katie OdgaardZyme CommunicationsTel: +44 (0)7787 502 947Email katie.odgaard@zymecommunications.comAt Domainex:Joanne McCuddenHead of Business DevelopmentEmail: joanne.mccudden@domainex.co.ukAbout Horizon Discovery www.horizondiscovery.comHorizon Discovery Limited (Horizon) is a leading provider of research tools to supporttranslational genomics research and the development of personalized medicines. The Company’sproprietary technology, GENESIS, is the world’s most precise genome editing technology. UsingGENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammaliancell-line quickly, reliably and without introducing unwanted and confounding genotypes and/orphenotypes.Horizon has harnessed GENESIS to create over 450 X-MAN cell lines, the world’s first source ofgenetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used byacademic and industry leaders to identify the effect of individual genetic mutations on drugactivity, patient responsiveness, and resistance, leading to the successful prediction of whichpatient sub-groups will respond to currently-available and future drug treatments. This enablesthe design of shorter, more focused, and less expensive clinical trials, ultimately providing thetools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutationsthat define their disease.In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN derived products andservices, with industrial application in: bio-pharmaceutical process optimization; clinical diagnosticdevelopment; drug discovery & development; and the provision of reference standards forgenomic-based clinical research platforms.GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.About Domainex Ltd. www.domainex.co.ukDomainex uses unique and proprietary technologies to resolve common bottlenecks facing thepharmaceutical and biotechnology industries in the post-genomic era. Major discovery gaps existbetween the vast amount of genomic information that is now available, the accessibility of thecorresponding proteins for use in target validation and drug discovery, and the identification ofrobust hits in a cost effective manner.Founded in 2001, Domainex is a privately owned company based in Cambridge, UK. Domainexhas developed a discovery platform, which enables rapid progression of drug discovery projectsfrom novel target through to Candidate Drug by means of its Combinatorial Domain Hunting
  3. 3. technology, LeadBuilder virtual hit screening software, and its integrated approach to medicinaland computational chemistry.Domainex’s patented CDH technology enables the cloning and expression of soluble drug targetprotein domains in E. coli, followed by the identification of those constructs that are able to bind aligand. Domainex has also developed LeadBuilder - a virtual screening approach for targetswhich is specifically aimed at quickly identifying hit molecules that are ideally suited for furtherdevelopment.The experienced medicinal chemistry team has a proven track record in supporting biotech oruniversity groups by providing expertise to take hit compounds through lead optimization and onto candidate selection. Three compounds to date arising from these collaborations are currentlyin clinical evaluation, with two additional drugs in preclinical studies.About The Institute of Cancer Research(ICR) is one of the world’s most influential cancer research institutes. For more information visitwww.icr.ac.ukScientists and clinicians at the ICR are working every day to make a real impact on cancerpatients’ lives. Through its unique partnership with The Royal Marsden Hospital and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutionscannot. Together the two organisations are rated in the top four cancer centres globally.The ICR has an outstanding record of achievement dating back more than 100 years. It providedthe first convincing evidence that DNA damage is the basic cause of cancer, laying the foundationfor the now universally accepted idea that cancer is a genetic disease. Today it leads the world atisolating cancer-related genes and discovering new targeted drugs for personalised cancertreatment. The Cancer Therapeutics Unit and Drug Development Unit at the ICR and The RoyalMarsden were recently honoured with the 2012 American Association for Cancer Research TeamScience Award for the “tremendous impact” of their preclinical and clinical studies.As a college of the University of London, the ICR provides postgraduate higher education ofinternational distinction. It has charitable status and relies on support from partner organisations,charities and the general public.The ICR’s mission is to make the discoveries that defeat cancer.